Adrian (Ad) Rawcliffe has served as our Chief Executive Officer since September 2019 and is a member of our Executive Team. Previously, he served as our Chief Financial Officer from March 2015 through September 2019.

Mr. Rawcliffe has over 20 years of experience within the biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. He joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture‑capital business. Mr. Rawcliffe currently serves as a non‑executive director of WAVE Life Sciences (NASDAQ: WVE).

Mr. Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.

William (Bill) Bertrand has served as our Chief Operating Officer since March 2017 and is responsible for operational functions including business operations, legal/IP,  compliance, human resources, quality, corporate affairs (including communications and investor relations) and IM.  He is a member of our Executive Team and also serves as the company’s Chief Compliance Officer.

Mr. Bertrand’s prior experience includes a 12 year tenure at MedImmune, where he served as its first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company’s $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. (Nasdaq: ARDX) and has served as a member of the board of directors of several private companies including Trustwave and Inotek Pharmaceuticals. Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.

Christopher (Chris) Hill has served as our Chief Financial Officer since September 10, 2025 and is a member of our Executive Team. He leads our financial operations and strategy.

Mr. Hill has over 10 years experience of serving in chief financial officer and chief operating officer roles in public and private life science companies. From September 2021 through September 9, 2025, he served as Chief Financial Officer and Chief Operating Officer (“COO”) of Istesso Limited, a private drug development company with pre-clinical to phase IIb assets developing new therapies in auto-immune and fibrotic diseases. Previously, Mr. Hill served as part-time Chief Financial Officer of Ixaka Limited, a private cell therapy company, from April 2020 through September 2021 and as Finance Director of OxSonics Therapeutics Limited, a private clinical stage therapeutics company developing improved drug delivery solutions to solid tumour cancers, from March 2019 through September 2021. He also previously served as part-time Chief Financial Officer of Luke Hughes and Company Limited, a private furniture manufacturer, from March 2018 through June 2019 where he oversaw a corporate restructure.

Mr. Hill served as Chief Financial Officer and a member of the Board of Directors of Oxford Pharmascience Group Plc, formerly a publicly listed drug development company on AIM focused on gastro-safe NSAIDs, from October 2013 through January 2018. Mr. Hill had responsibility for the financial, legal and HR functions within the group and for AIM and other regulatory reporting. During his tenure, the company underwent a demerger, and its operations were spun out into Abaco Capital (AIM: ABAA) and private company, Oxford Pharmascience Limited. His other prior roles include serving as Group Financial Controller at Ora Capital Partners Limited, previously an AIM-listed investment vehicle, from July 2010 through October 2013, and as Audit Senior at international audit, professional services and consulting firm, Grant Thornton UK LLP, from June 2005 to June 2010. He currently serves as a director of private companies, Connexion Therapeutics Group Limited and CJH Financial Limited.

Mr. Hill is a chartered accountant and holds a B.A. degree in Economics and Public Policy from Leeds Metropolitan University.

Kerry has served as our General Counsel since October 2015. She heads up the teams in legal, intellectual property, corporate compliance and clinical compliance, COSHH/Biological Safety (BioCOSHH) and HTA Compliance teams.

She graduated from Imperial College with a Bsc. Hons in Biotechnology before qualifying as an English solicitor. Having over 20 years of experience, she started her legal career at magic circle firm, Linklaters before moving to IP niche firm Bird and Bird. From there, Kerry became sole counsel at Innovision, Research and Technology plc and then Regional Counsel, Europe at Broadcom Inc. Subsequently, Kerry was a commercial IP partner and co-head of the life sciences practice area at Pennington’s Manches LLP advising on a wide variety of life sciences transactions including licensing, collaboration and research, IP exploitation and strategy, life sciences regulatory advice, manufacturing, clinical trial agreements, technology transfer and supply and distribution agreements.